Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Cora N. Sternberg, Giuseppe Procopio et al.|Clinical Cancer Research|2019Cited by 240
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Vanna Chiarion‐Sileni, Andrea Antonuzzo et al.|Journal of Neuro-Oncology|2014Cited by 119
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.Paola Queirolo, Paolo A. Ascierto, Francesco Spagnolo et al.|Journal of Clinical Oncology|2013Cited by 11
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)Ugo De Giorgi, Cora N. Sternberg, Giuseppe Procopio et al.|Annals of Oncology|2017Cited by 3
Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.Ugo De Giorgi, Cora N. Sternberg, Giuseppe Procopio et al.|Journal of Clinical Oncology|2019Cited by 2